{"id":"ted","safety":{"commonSideEffects":[{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Appetite suppression"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nervousness"},{"rate":null,"effect":"Tachycardia"}]},"_chembl":{"chemblId":"CHEMBL4789575","moleculeType":"Unknown","molecularWeight":"2598.50"},"_dailymed":{"setId":"75672079-589f-451a-bdbf-eaebcfcc80a9","title":"SIVEXTRO (TEDIZOLID PHOSPHATE) TABLET, FILM COATED SIVEXTRO (TEDIZOLID PHOSPHATE) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [MERCK SHARP & DOHME LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"TED (tetrahydrozoline derivative or similar sympathomimetic) acts as a central nervous system stimulant, likely through dopamine and norepinephrine reuptake inhibition or release. The exact mechanism depends on the specific formulation marketed by Shire, which may be a branded version of an established ADHD therapeutic.","oneSentence":"TED is a prodrug that is converted to active metabolites to treat attention-deficit/hyperactivity disorder (ADHD) by enhancing central nervous system stimulation.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:37:42.328Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Attention-deficit/hyperactivity disorder (ADHD)"}]},"trialDetails":[{"nctId":"NCT06166537","phase":"NA","title":"GRACE: Evaluating Compression Stockings in Patients That Require Extended Duration Pharmacological Thromboprophylaxis","status":"RECRUITING","sponsor":"Imperial College London","startDate":"2024-04-27","conditions":"Venous Thromboembolism, Surgery","enrollment":8608},{"nctId":"NCT06307613","phase":"PHASE3","title":"A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease","status":"TERMINATED","sponsor":"argenx","startDate":"2024-03-27","conditions":"Thyroid Eye Disease","enrollment":102},{"nctId":"NCT06307626","phase":"PHASE3","title":"A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease.","status":"TERMINATED","sponsor":"argenx","startDate":"2024-03-28","conditions":"Thyroid Eye Disease","enrollment":105},{"nctId":"NCT07462130","phase":"PHASE1, PHASE2","title":"An Efficacy and Safety Study of NTB003 in Participants With Thyroid Eye Disease (TED)","status":"NOT_YET_RECRUITING","sponsor":"Nanjing Chia-tai Tianqing Pharmaceutical","startDate":"2026-03-01","conditions":"Thyroid Eye Disease","enrollment":74},{"nctId":"NCT05823766","phase":"","title":"Transforming Research and Clinical Knowledge in Traumatic Brain Injury Epileptogenesis Project (TRACK-TBI EPI)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2022-03-01","conditions":"Traumatic Brain Injury, Post-traumatic Epilepsy","enrollment":300},{"nctId":"NCT06226545","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease","status":"COMPLETED","sponsor":"Lassen Therapeutics Inc.","startDate":"2024-03-05","conditions":"Thyroid Eye Disease, Graves Ophthalmopathy, Graves Orbitopathy","enrollment":41},{"nctId":"NCT07447908","phase":"","title":"Ted Rogers Understanding of Exacerbations in Heart Failure 2: Monitor","status":"NOT_YET_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2026-03-16","conditions":"Heart Failure, Heart Failure - NYHA II - IV, Heart Failure Patients","enrollment":360},{"nctId":"NCT07444190","phase":"","title":"Psychological Burden of Thyroid Eye Disease","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2025-01-01","conditions":"Thyroid Eye Disease, TED","enrollment":20},{"nctId":"NCT07142642","phase":"PHASE1","title":"A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Teprotumumab (AMG 632) Administered Intravenously in Healthy Chinese Participants","status":"COMPLETED","sponsor":"Amgen","startDate":"2025-08-26","conditions":"Healthy Volunteers","enrollment":20},{"nctId":"NCT07423013","phase":"NA","title":"Evaluating the Efficacy and Safety of Teprotumumab N01 in Patients With Thyroid Eye Disease.","status":"RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2025-11-11","conditions":"Thyroid Eye Disease","enrollment":50},{"nctId":"NCT05517447","phase":"PHASE3","title":"Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Immunovant Sciences GmbH","startDate":"2022-11-06","conditions":"Thyroid Eye Disease","enrollment":180},{"nctId":"NCT06384547","phase":"PHASE3","title":"A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)","status":"COMPLETED","sponsor":"Viridian Therapeutics, Inc.","startDate":"2024-05-23","conditions":"Thyroid Eye Disease","enrollment":231},{"nctId":"NCT06106828","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-11-15","conditions":"Thyroid Eye Disease","enrollment":127},{"nctId":"NCT01915797","phase":"","title":"Tumor and Development (TED)","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2013-06-01","conditions":"Tumor and Abnormalities of the Development","enrollment":998},{"nctId":"NCT06569758","phase":"PHASE1","title":"A Study of GenSci098 in Subjects With Active Thyroid Eye Disease","status":"RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2024-09-24","conditions":"Safety, Tolerability, GenSci098","enrollment":76},{"nctId":"NCT07387159","phase":"NA","title":"Effect of MiYOSMART iQ Spectacle Lenses on Myopia Progression in Children","status":"RECRUITING","sponsor":"Hoya Lens Rus LLC","startDate":"2026-02-04","conditions":"Myopia, Child Myopia Progression","enrollment":70},{"nctId":"NCT04884282","phase":"PHASE2","title":"Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Ricerca Traslazionale","startDate":"2021-10-12","conditions":"Metastatic Non Small Cell Lung Cancer","enrollment":105},{"nctId":"NCT06088979","phase":"PHASE2","title":"A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye Disease","status":"RECRUITING","sponsor":"Tourmaline Bio, Inc.","startDate":"2024-02-19","conditions":"Thyroid Eye Disease","enrollment":81},{"nctId":"NCT07378267","phase":"NA","title":"Effect of Intermittent Fasting and Mediterranean Diet on Body Composition and Nutritional Intake","status":"COMPLETED","sponsor":"Selcuk University","startDate":"2023-02-18","conditions":"Obesity & Overweight","enrollment":100},{"nctId":"NCT06401044","phase":"PHASE1, PHASE2","title":"A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease","status":"RECRUITING","sponsor":"Amgen","startDate":"2024-05-30","conditions":"Thyroid Eye Disease","enrollment":88},{"nctId":"NCT05002998","phase":"PHASE4","title":"TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study","status":"COMPLETED","sponsor":"Amgen","startDate":"2021-09-16","conditions":"Thyroid Eye Disease","enrollment":313},{"nctId":"NCT07155668","phase":"PHASE3","title":"A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Viridian Therapeutics, Inc.","startDate":"2025-07-01","conditions":"Thyroid Eye Disease","enrollment":87},{"nctId":"NCT07308964","phase":"PHASE4","title":"Comparison of the Efficacy and Safety of 4 vs. 8 Treatments With Tepezza (Teprotumumab) for Thyroid Eye Disease","status":"NOT_YET_RECRUITING","sponsor":"Sheba Medical Center","startDate":"2026-01","conditions":"Thyroid Eye Disease, Thyroid Eye Disease, TED, Thyroid Eye Disease (TED)","enrollment":40},{"nctId":"NCT07211776","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease","status":"RECRUITING","sponsor":"Zai Lab (Shanghai) Co., Ltd.","startDate":"2025-12-05","conditions":"Thyroid Eye Disease (TED)","enrollment":99},{"nctId":"NCT05524571","phase":"PHASE3","title":"Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Immunovant Sciences GmbH","startDate":"2023-01-05","conditions":"Thyroid Eye Disease","enrollment":100},{"nctId":"NCT06812325","phase":"PHASE3","title":"A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Viridian Therapeutics, Inc.","startDate":"2025-02-03","conditions":"Thyroid Eye Disease (TED)","enrollment":321},{"nctId":"NCT05517421","phase":"PHASE3","title":"Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease","status":"COMPLETED","sponsor":"Immunovant Sciences GmbH","startDate":"2022-11-23","conditions":"Thyroid Eye Disease","enrollment":114},{"nctId":"NCT06467435","phase":"PHASE1","title":"Evaluation of K9 in Subjects With Thyroid Eye Disease (TED)","status":"RECRUITING","sponsor":"Peter Timoney","startDate":"2024-11-06","conditions":"Thyroid Eye Disease","enrollment":13},{"nctId":"NCT07246200","phase":"NA","title":"TED Stocking vs. Reparel Garment After Hip Replacement","status":"ACTIVE_NOT_RECRUITING","sponsor":"Reparel","startDate":"2022-01-01","conditions":"Osteoarthritis (OA) of the Hip","enrollment":50},{"nctId":"NCT04751942","phase":"NA","title":"Reparel Knee Sleeve vs. TED Hose for Post-op Swelling, Pain and Range of Motion After Total Knee Replacement","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2023-10-20","conditions":"Osteoarthritis Knees Both","enrollment":23},{"nctId":"NCT06021054","phase":"PHASE3","title":"An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED) (THRIVE-2)","status":"COMPLETED","sponsor":"Viridian Therapeutics, Inc.","startDate":"2023-11-14","conditions":"Thyroid Eye Disease","enrollment":188},{"nctId":"NCT06625411","phase":"PHASE3","title":"An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Viridian Therapeutics, Inc.","startDate":"2024-08-27","conditions":"Thyroid Eye Disease","enrollment":117},{"nctId":"NCT06625398","phase":"PHASE3","title":"An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Viridian Therapeutics, Inc.","startDate":"2024-08-27","conditions":"Thyroid Eye Disease","enrollment":195},{"nctId":"NCT07085117","phase":"","title":"Real World Study to Describe the Effectiveness and Safety of Teprotumumab Among Thyroid Eye Disease Patients","status":"COMPLETED","sponsor":"Amgen","startDate":"2025-07-02","conditions":"Thyroid Eye Disease","enrollment":5},{"nctId":"NCT07152340","phase":"PHASE4","title":"The Safety and Efficacy of Sequential Hormone Therapy and IBI311 Therapy in Patients With Active Moderate to Severe TAO in the Initial Treatment.","status":"RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2025-04-10","conditions":"Thyroid Associated Ophthalmopathies","enrollment":64},{"nctId":"NCT07152366","phase":"PHASE4","title":"Efficacy and Safety of Sequential Hormone Therapy and Tetuzumab Therapy in Patients With Moderate to Severe TAO in the Active Stage After Glucocorticoid Treatment.","status":"RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2025-04-15","conditions":"Thyroid Associated Ophthalmopathies","enrollment":96},{"nctId":"NCT07152392","phase":"PHASE4","title":"Evaluation of the Efficacy and Safety Observation of IBI311 Treatment in Patients With Inactive TAO","status":"RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2025-04-15","conditions":"Thyroid Associated Ophthalmopathies","enrollment":50},{"nctId":"NCT05556057","phase":"NA","title":"Feasibility of Mindfulness Meditation Training and Home Practice in Persons With Spinal Cord Injury","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2022-12-06","conditions":"Spinal Cord Injuries","enrollment":65},{"nctId":"NCT05176639","phase":"PHASE3","title":"A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants With Thyroid Eye Disease (TED) ( THRIVE )","status":"COMPLETED","sponsor":"Viridian Therapeutics, Inc.","startDate":"2021-12-03","conditions":"Thyroid Eye Disease","enrollment":113},{"nctId":"NCT07056114","phase":"","title":"Multi-modal Medical Images for Extraocular Muscle Fibrosis Assessment","status":"COMPLETED","sponsor":"Tianjin Eye Hospital","startDate":"2020-01-01","conditions":"Thyroid Eye Disease, TED","enrollment":58},{"nctId":"NCT05683496","phase":"PHASE1, PHASE2","title":"Efficacy and Safety of Lonigutamab in Subjects With Thyroid Eye Disease (TED)","status":"COMPLETED","sponsor":"ACELYRIN Inc.","startDate":"2023-02-14","conditions":"Thyroid Eye Disease","enrollment":31},{"nctId":"NCT05561933","phase":"NA","title":"Scaling Well-Being for Educators During COVID-19","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2022-10-21","conditions":"Anxiety, Depression","enrollment":829},{"nctId":"NCT04713007","phase":"NA","title":"Improving Quality of Life for Colon Cancer Patients and Their Caregivers","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Hawaii","startDate":"2021-06-03","conditions":"Colon Cancer","enrollment":60},{"nctId":"NCT06927375","phase":"PHASE4","title":"A Study on the Combined Use of Tocilizumab and Flupentixol-Melitracen in the Treatment of Thyroid-Associated Ophthalmopathy","status":"RECRUITING","sponsor":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","startDate":"2024-12-12","conditions":"Thyroid-Associated Ophthalmopathy","enrollment":60},{"nctId":"NCT06311461","phase":"NA","title":"Effects of Acupuncture on Symptoms of Stable Angina","status":"RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2024-04-01","conditions":"Angina, Stable","enrollment":112},{"nctId":"NCT02954458","phase":"PHASE3","title":"Long-term Safety and Efficacy Study of Teduglutide in Pediatric Participants With Short Bowel Syndrome (SBS)","status":"COMPLETED","sponsor":"Shire","startDate":"2017-01-09","conditions":"Short Bowel Syndrome","enrollment":61},{"nctId":"NCT06891989","phase":"NA","title":"Effects of a Mobile App-Based Mindfulness Intervention in Persons with Spinal Cord Injury and Chronic Pain","status":"NOT_YET_RECRUITING","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2026-01-01","conditions":"Spinal Cord Injuries","enrollment":282},{"nctId":"NCT02949362","phase":"PHASE3","title":"Long-term Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome Who Completed the TED-C13-003 Study","status":"COMPLETED","sponsor":"Shire","startDate":"2016-12-09","conditions":"Short Bowel Syndrome","enrollment":29},{"nctId":"NCT06112340","phase":"PHASE2, PHASE3","title":"Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)","status":"RECRUITING","sponsor":"Sling Therapeutics, Inc.","startDate":"2023-10-11","conditions":"Thyroid Eye Disease, Graves Orbitopathy, Endocrine System Diseases","enrollment":75},{"nctId":"NCT05276063","phase":"PHASE2, PHASE3","title":"A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sling Therapeutics, Inc.","startDate":"2022-07-01","conditions":"Thyroid Eye Disease, Graves Orbitopathy, Endocrine System Diseases","enrollment":90},{"nctId":"NCT04737330","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED)","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-11-29","conditions":"Thyroid Eye Disease, Graves Orbitopathy","enrollment":28},{"nctId":"NCT01868997","phase":"PHASE2","title":"Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-07","conditions":"Thyroid Associated Ophthalmopathies, Thyroid-Associated Ophthalmopathy","enrollment":88},{"nctId":"NCT04331392","phase":"NA","title":"Online Memory Intervention for Individuals with Traumatic Brain Injury","status":"RECRUITING","sponsor":"Toronto Rehabilitation Institute","startDate":"2018-10-30","conditions":"Brain Injuries, Traumatic, Brain Injury Traumatic Severe, Brain Injury Traumatic Moderate","enrollment":84},{"nctId":"NCT06095401","phase":"NA","title":"Swelling Management After Knee Replacement","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2024-02-21","conditions":"Arthroplasties, Knee Replacement","enrollment":58},{"nctId":"NCT06367517","phase":"","title":"Tocilizumab in Corticosteroid-Resistant Graves' Orbitopathy (Thyroid Eye Disease)","status":"RECRUITING","sponsor":"Medical University of Warsaw","startDate":"2021-05-20","conditions":"Orbitopathy, Graves, Thyroid Eye Disease, Ophthalmopathy","enrollment":30},{"nctId":"NCT06359795","phase":"NA","title":"Exploring the Value of 18F-AlF-FAPI PET/CT in Assessing the Activity of Thyroid Eye Disease","status":"RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2023-12-15","conditions":"Thyroid Eye Disease","enrollment":50},{"nctId":"NCT05795621","phase":"PHASE2, PHASE3","title":"A Study of IBI311 in Subjects With Active Thyroid Eye Disease","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2023-02-14","conditions":"Thyroid Eye Disease","enrollment":115},{"nctId":"NCT04832087","phase":"","title":"Pediatric Teduglutide Registry","status":"COMPLETED","sponsor":"Boston Children's Hospital","startDate":"2021-05-18","conditions":"Short Bowel Syndrome","enrollment":142},{"nctId":"NCT05162404","phase":"NA","title":"Video Education to Improve Rural Cancer Care Delivery","status":"COMPLETED","sponsor":"University of Hawaii","startDate":"2022-01-05","conditions":"Cancer","enrollment":14},{"nctId":"NCT02393183","phase":"PHASE2, PHASE3","title":"The Effect of a New Antioxidant Combination (ASTED) on Mild Thyroid Eye Disease (TED)","status":"WITHDRAWN","sponsor":"Iran University of Medical Sciences","startDate":"2019-07-15","conditions":"Thyroid Eye Disease","enrollment":""},{"nctId":"NCT03596164","phase":"PHASE3","title":"An Extension Study of Teduglutide in Japanese Participants With Short Bowel Syndrome Who Completed 24 Weeks of Treatment in SHP633-306 or TED-C14-004","status":"COMPLETED","sponsor":"Takeda","startDate":"2018-07-09","conditions":"Short Bowel Syndrome","enrollment":11},{"nctId":"NCT03455881","phase":"","title":"Phenotypic and Genetic Assessment of Tracheal and Esophageal Birth Defects in Patients","status":"UNKNOWN","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2018-03-28","conditions":"Tracheoesophageal Fistula, Esophageal Atresia, Laryngeal Cleft","enrollment":360},{"nctId":"NCT05671120","phase":"NA","title":"Transcutaneous Levator Recession for Non-thyroid Lid Retraction","status":"COMPLETED","sponsor":"Al-Azhar University","startDate":"2019-01-01","conditions":"Eye Diseases","enrollment":19},{"nctId":"NCT05008692","phase":"","title":"Apple-CPET Ted Rogers Understanding Exacerbations of Heart Failure","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2020-12-01","conditions":"Heart Failure, Heart Failure, Systolic, Heart Failure, Diastolic","enrollment":200},{"nctId":"NCT05154110","phase":"NA","title":"Comparison of Two Techniques for Maintaining Range of Motion","status":"COMPLETED","sponsor":"Bahria University","startDate":"2022-01-20","conditions":"Healthy","enrollment":22},{"nctId":"NCT05404438","phase":"NA","title":"Mouth Breathing Habits Improvement Intervention","status":"COMPLETED","sponsor":"National Yang Ming Chiao Tung University","startDate":"2018-09-09","conditions":"OSA","enrollment":24},{"nctId":"NCT04818814","phase":"NA","title":"SCI Pain App Intervention Study","status":"TERMINATED","sponsor":"Baylor College of Medicine","startDate":"2021-10-04","conditions":"Spinal Cord Injuries, Chronic Pain","enrollment":11},{"nctId":"NCT05015127","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy and Safety of HBM9161 on Moderate to Severe Thyroid Eye Disease","status":"UNKNOWN","sponsor":"Harbour BioMed (Guangzhou) Co. Ltd.","startDate":"2021-09-22","conditions":"Thyroid Ophthalmopathy","enrollment":36},{"nctId":"NCT05210491","phase":"NA","title":"The Effect of Varying Brightness on Palpebral Aperture","status":"UNKNOWN","sponsor":"University of Edinburgh","startDate":"2022-01-14","conditions":"Eyelid Ptoses","enrollment":40},{"nctId":"NCT01738243","phase":"PHASE4","title":"Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease","status":"TERMINATED","sponsor":"University of California, Los Angeles","startDate":"2013-12","conditions":"Thyroid Eye Disease","enrollment":2},{"nctId":"NCT04982978","phase":"NA","title":"Information Interventions to Reduce Vaping in a Student Population","status":"COMPLETED","sponsor":"Western University","startDate":"2021-01-07","conditions":"Vaping Related Disorder","enrollment":77},{"nctId":"NCT03860688","phase":"PHASE2, PHASE3","title":"Effects of Oral Glucose and Teduglutide on Plasma Lipoproteins","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2019-05-01","conditions":"Hyperlipidemias","enrollment":15},{"nctId":"NCT03972787","phase":"NA","title":"Effects of a Proactive Social Robot for Older Adults in Reducing Loneliness and Social Isolation","status":"COMPLETED","sponsor":"Baycrest","startDate":"2019-03-05","conditions":"Loneliness, Mood, Quality of Life","enrollment":54},{"nctId":"NCT03963765","phase":"NA","title":"Transepidermal Application of Metilaminolevulinate in Daylight PDT in the Treatment of Photodamaged Skin","status":"COMPLETED","sponsor":"Universidade Federal Fluminense","startDate":"2017-02-03","conditions":"Skin Diseases","enrollment":40},{"nctId":"NCT04433936","phase":"","title":"Corneal Tomographic Parameters in TGD","status":"COMPLETED","sponsor":"Ameera Gamal Abdelhameed","startDate":"2018-02-01","conditions":"Keratoconus, Corneal Ectasia, Thyroid Eye Disease","enrollment":100},{"nctId":"NCT03099031","phase":"","title":"Non Interventional Study of the Validation of the Ottawa Score in Cancer Patients With Venous Thromboembolism (VTE)","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2015-05","conditions":"Venous Thromboembolism","enrollment":420},{"nctId":"NCT02664090","phase":"","title":"Hemodynamic Assessment With Trans-esophageal Doppler (TED) During Prone Ventilation in ARDS Patients","status":"COMPLETED","sponsor":"Sanjay Gandhi Postgraduate Institute of Medical Sciences","startDate":"2016-01-20","conditions":"Respiratory Distress Syndrome, Adult","enrollment":26},{"nctId":"NCT01996813","phase":"NA","title":"Compression Stocking Use in Shoulder Arthroscopy in Beach Chair","status":"COMPLETED","sponsor":"Loyola University","startDate":"2013-03-28","conditions":"Obesity, Shoulder Impingement","enrollment":23},{"nctId":"NCT03177590","phase":"NA","title":"Recording Facial and Vocal Emotional Productions in Children With Autism as Part of the JEMImE Project","status":"COMPLETED","sponsor":"Fondation Lenval","startDate":"2016-05-10","conditions":"Autism, Pervasive Developmental Disorder","enrollment":35},{"nctId":"NCT02155049","phase":"PHASE3","title":"Treatment of Soft Tissue Expansion in Inactive Thyroid Eye Disease Patients Using Drops of Prostaglandin Analogues","status":"COMPLETED","sponsor":"Rabin Medical Center","startDate":"2014-11","conditions":"Thyroid Associated Ophthalmopathies","enrollment":10},{"nctId":"NCT03097198","phase":"NA","title":"Effect of Plum-blossom Needle vs. Tropicamide Eye Drops on Juvenile Myopia","status":"UNKNOWN","sponsor":"Wenzhou Medical University","startDate":"2016-12","conditions":"Myopia","enrollment":98},{"nctId":"NCT00954057","phase":"PHASE2","title":"Pilot Study to Determine Safety and Efficacy of Orbital Injections of LIPO-102 in Patients With Symptomatic Exophthalmos Associated With Thyroid-related Eye Disease (TED)","status":"COMPLETED","sponsor":"Neothetics, Inc","startDate":"2009-09","conditions":"Thyroid-Related Eye Disease","enrollment":11},{"nctId":"NCT01680393","phase":"NA","title":"Sequential Compression Device (SCD) for Stabilizing Hemodynamics in the Beach Chair Position","status":"UNKNOWN","sponsor":"Bispebjerg Hospital","startDate":"2011-05","conditions":"Hypotension","enrollment":60},{"nctId":"NCT00235807","phase":"NA","title":"Multi-Site Randomized Clinical Study of Tinnitus Treatment Methods","status":"COMPLETED","sponsor":"US Department of Veterans Affairs","startDate":"2004-06","conditions":"Tinnitus","enrollment":144},{"nctId":"NCT00991497","phase":"NA","title":"A Trial to Compare the Outcome of Localised Varicosity Compression for 24 Hours and 5 Days After Foam Sclerotherapy to Truncal Varices","status":"COMPLETED","sponsor":"Gloucestershire Hospitals NHS Foundation Trust","startDate":"2007-01","conditions":"Varicose Veins","enrollment":124}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2568,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"TED","genericName":"TED","companyName":"Shire","companyId":"shire","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TED is a prodrug that is converted to active metabolites to treat attention-deficit/hyperactivity disorder (ADHD) by enhancing central nervous system stimulation. Used for Attention-deficit/hyperactivity disorder (ADHD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}